Next-Generation Luminescence-Based Radiation Therapy Platform
Legal Citation
Summary of the Inventive Concept
A comprehensive radiation therapy system leveraging advanced luminescence-based sensors, machine learning, and real-time feedback to optimize treatment outcomes and minimize side effects.
Background and Problem Solved
Conventional radiation therapy often lacks real-time optimization, leading to suboptimal treatment outcomes and increased risk of radiation-induced toxicity. The original patent's luminescence-based method for precise delivery of ion beam therapy, while innovative, has limitations in terms of real-time optimization and personalized treatment planning. The new inventive concept addresses these limitations by integrating advanced sensors, machine learning, and real-time feedback to create a next-generation radiation therapy platform.
Detailed Description of the Inventive Concept
The new inventive concept comprises a luminescence-based sensor array for detecting ion beam fluence and energy distribution, a machine learning module for predicting optimal radiation therapy parameters, and a radiation therapy control system for adjusting ion beam delivery in response to said predicted parameters. This system enables real-time optimization of radiation therapy, ensuring that the ion beam is delivered with optimal energy and fluence to maximize treatment efficacy while minimizing side effects. Additionally, the system can be integrated with personalized radiation therapy planning, allowing for simulation-based optimization of treatment parameters based on individual patient anatomy and tumor characteristics.
Novelty and Inventive Step
The new inventive concept's integration of luminescence-based sensors, machine learning, and real-time feedback represents a significant departure from the original patent's method, which relied on static marker placement and lacked real-time optimization capabilities. The novel combination of these elements enables a paradigm shift in radiation therapy, allowing for truly personalized and optimized treatment outcomes.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different luminescent materials, sensor geometries, or machine learning algorithms. Variations could also include the integration of additional modalities, such as imaging or robotics, to further enhance treatment outcomes.
Potential Commercial Applications and Market
The next-generation radiation therapy platform has significant commercial potential in the oncology market, with potential applications in hospitals, cancer centers, and research institutions. The system's ability to optimize treatment outcomes and minimize side effects could lead to increased adoption and market share, potentially disrupting the traditional radiation therapy market.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Radiation oncology and medical physics, with expertise in ion beam therapy, luminescence-based dosimetry, and advanced radiation treatment technologies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in medical physics, radiation oncology, or biomedical engineering, possessing knowledge of radiation therapy techniques, sensor technologies, and computational modeling approaches
Obviousness Rationale
A PHOSITA would recognize that the PTD's integration of machine learning and real-time sensor feedback represents a natural progression of the source patent's luminescence-based radiation therapy approach. The core concept of using luminescent markers for precise ion beam delivery is extended through predictable technological advancements in sensor array design and computational optimization. The variations demonstrate incremental improvements that would be obvious to a skilled practitioner seeking to enhance radiation therapy precision and personalization.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,806 |
|---|---|
| Title | Luminescence-based method for precise delivery of ion beam therapy |
| Assignee(s) | United States of America as represented by the Secretary of the Navy |